Cabaletta Bio Inc (CABA)

$1.77 +0.06 (3.51%)
Market Cap 156.41M
Revenue (ttm) 0.00
Net Income (ttm) -115.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,961,454
Avg Vol 2,000,542
Day's Range N/A - N/A
Shares Out 91.47M
Stochastic %K 92%
Beta 2.74
Analysts Strong Sell
Price Target $11.89

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythe...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 759 3100
Address:
2929 Arch Street, Suite 600, Philadelphia, United States
4976f2e
4976f2e Aug. 18 at 9:02 PM
$CABA Interesting movement here. Based off the volume and price action I’d expect some positive news in the next two weeks.
0 · Reply
mgm6
mgm6 Aug. 18 at 7:09 PM
$CABA 25-30% up and now stuck here 1.50 to 1.75... let the stock fly high... Come ooooon Raaaawr
0 · Reply
WastedTrader
WastedTrader Aug. 18 at 6:37 PM
$CABA 1 positive press release and this will jump $5 over night
0 · Reply
Himtan1
Himtan1 Aug. 18 at 2:58 PM
$CABA I've averaged down to 1.70 and finally got some profit!
0 · Reply
vu_jade
vu_jade Aug. 18 at 2:52 PM
$CABA just starting
0 · Reply
Moonman321
Moonman321 Aug. 18 at 2:38 AM
$QBTS 🚀 $CABA we’re going to run into Jackson hole Jerome Powell cuts twice perhaps first cut 50 basis points, catching everybody off guard and then Trump will take over with his new pic at beginning of next year This is going to fly Caba 🚀
0 · Reply
Kawasaki1
Kawasaki1 Aug. 18 at 1:38 AM
$CABA If You are looking for a 10 X play...this is IT!
1 · Reply
vu_jade
vu_jade Aug. 15 at 4:59 PM
$CABA your penny bio champion!
0 · Reply
Wirralboy
Wirralboy Aug. 15 at 2:42 PM
$CABA looks like it wants to get higher which was not the case for a few weeks. Market down on bad news this week- would have been interesting had it not been
0 · Reply
Ahouli09
Ahouli09 Aug. 15 at 10:33 AM
$CABA
0 · Reply
Latest News on CABA
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:30 AM EDT - 11 days ago

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 19 days ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT NGNE NTLA QURE RCKT

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 9:54 AM EDT - 2 months ago

Cabaletta Bio Announces Pricing of Public Offering of Securities

Cabaletta Bio: Sector Headwinds And Funding Issues

Jun 11, 2025, 9:49 AM EDT - 2 months ago

Cabaletta Bio: Sector Headwinds And Funding Issues

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:15 AM EDT - 2 months ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

Jun 11, 2025, 6:00 AM EDT - 2 months ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 2 months ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

May 15, 2025, 7:00 AM EDT - 3 months ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 31, 2025, 7:00 AM EDT - 5 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Mar 19, 2025, 7:00 AM EDT - 5 months ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 6 months ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 10:21 AM EST - 6 months ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 6 months ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Feb 11, 2025, 8:00 AM EST - 6 months ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Jan 29, 2025, 8:00 AM EST - 7 months ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Cabaletta Bio: Finding Optimism In Dire Straits

Jan 6, 2025, 2:28 PM EST - 8 months ago

Cabaletta Bio: Finding Optimism In Dire Straits

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Oct 22, 2024, 11:41 AM EDT - 10 months ago

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Sep 25, 2024, 4:30 PM EDT - 11 months ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 28, 2024, 1:42 PM EDT - 1 year ago

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

Jun 14, 2024, 2:00 AM EDT - 1 year ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 15, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 13, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 27, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Feb 1, 2024, 4:30 PM EST - 1 year ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 31, 2024, 2:53 AM EST - 1 year ago

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Dec 11, 2023, 5:58 AM EST - 1 year ago

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Buy Cabaletta Bio's Promising SLE Treatment

Dec 10, 2023, 2:44 AM EST - 1 year ago

Buy Cabaletta Bio's Promising SLE Treatment

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 4:30 PM EST - 1 year ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 28, 2023, 3:55 PM EST - 1 year ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 7:00 AM EST - 1 year ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Nov 6, 2023, 8:15 AM EST - 1 year ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Sep 19, 2023, 4:56 AM EDT - 2 years ago

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

Jul 24, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

Cabaletta Bio to Present at the Jefferies Healthcare Conference

May 31, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Present at the Jefferies Healthcare Conference

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

May 22, 2023, 4:30 PM EDT - 2 years ago

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

TipRanks reveals the top 10 health care sector analysts of the past decade

May 21, 2023, 8:20 AM EDT - 2 years ago

TipRanks reveals the top 10 health care sector analysts of the past decade

CYH EXAS MRNA NVAX ORGO PFE RARE

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

May 17, 2023, 10:16 PM EDT - 2 years ago

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

Cabaletta Bio Announces Proposed Public Offering of Common Stock

May 17, 2023, 4:01 PM EDT - 2 years ago

Cabaletta Bio Announces Proposed Public Offering of Common Stock

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

May 16, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 2, 2023, 4:35 PM EDT - 2 years ago

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

4976f2e
4976f2e Aug. 18 at 9:02 PM
$CABA Interesting movement here. Based off the volume and price action I’d expect some positive news in the next two weeks.
0 · Reply
mgm6
mgm6 Aug. 18 at 7:09 PM
$CABA 25-30% up and now stuck here 1.50 to 1.75... let the stock fly high... Come ooooon Raaaawr
0 · Reply
WastedTrader
WastedTrader Aug. 18 at 6:37 PM
$CABA 1 positive press release and this will jump $5 over night
0 · Reply
Himtan1
Himtan1 Aug. 18 at 2:58 PM
$CABA I've averaged down to 1.70 and finally got some profit!
0 · Reply
vu_jade
vu_jade Aug. 18 at 2:52 PM
$CABA just starting
0 · Reply
Moonman321
Moonman321 Aug. 18 at 2:38 AM
$QBTS 🚀 $CABA we’re going to run into Jackson hole Jerome Powell cuts twice perhaps first cut 50 basis points, catching everybody off guard and then Trump will take over with his new pic at beginning of next year This is going to fly Caba 🚀
0 · Reply
Kawasaki1
Kawasaki1 Aug. 18 at 1:38 AM
$CABA If You are looking for a 10 X play...this is IT!
1 · Reply
vu_jade
vu_jade Aug. 15 at 4:59 PM
$CABA your penny bio champion!
0 · Reply
Wirralboy
Wirralboy Aug. 15 at 2:42 PM
$CABA looks like it wants to get higher which was not the case for a few weeks. Market down on bad news this week- would have been interesting had it not been
0 · Reply
Ahouli09
Ahouli09 Aug. 15 at 10:33 AM
$CABA
0 · Reply
mgm6
mgm6 Aug. 15 at 8:55 AM
$CABA vreak 1.75 and lets go to 2 level 🎊
0 · Reply
Moonman321
Moonman321 Aug. 14 at 7:06 PM
$CABA the domino effect began You’d have to be an idiot to have sold today Blue skies ahead Sheep 🐑 🐻 😂
1 · Reply
Enea1977
Enea1977 Aug. 14 at 4:11 PM
$CABA today just sellers....
1 · Reply
Ahouli09
Ahouli09 Aug. 14 at 10:57 AM
$CABA
1 · Reply
The1Ski
The1Ski Aug. 14 at 5:11 AM
$CABA Looks familiar. Buy low sell high
0 · Reply
StockScanners
StockScanners Aug. 14 at 1:59 AM
$CABA keep watch if this holds above 1.55
0 · Reply
mgm6
mgm6 Aug. 14 at 1:34 AM
$CABA sold some at 1.72 but regret and bought back at 1.61. didnt sell last run to 2.5 so i wish good luck to everybody and hopefully we will see digit around 4-5 again soon
0 · Reply
LifeisaMeme
LifeisaMeme Aug. 14 at 12:03 AM
$CABA We just keep winning and winning
0 · Reply
Chrisf720
Chrisf720 Aug. 13 at 8:04 PM
$CABA lets goo
0 · Reply
WoldanStanford
WoldanStanford Aug. 13 at 7:50 PM
$CABA whats up
0 · Reply
Daniel_Ocean
Daniel_Ocean Aug. 13 at 7:47 PM
$CABA this is why you don’t panic sell lads. Let’s keep the momentum going past $2
0 · Reply
Enea1977
Enea1977 Aug. 13 at 7:42 PM
$CABA very nice surprice...I believe in this stock...
0 · Reply